Diapositive 1

1122 / 1851

Bunn Jr PA. et al. J Thor Oncol 2016;11
New perspectives and future directions:
Is there a role for “mAbs” and immunotherapy in SCLC ?
Potential “targets of treatment”:
 Notch
 FGFR
 PI3KCA
 RET
 FAK
 CXCR4
 PARP
 PD-L1
 VEGFR